Can I suggest we restart a robust but positive discussion of the...

Can I suggest we restart a robust but positive discussion of the company under this “general discussion” thread? Disruptive posters have their own agenda but they need oxygen to fuel the chaos, just ignore them.

A number of posters have mentioned they are invested for the five clinical trials currently underway and I’m one that fits into this category. IMO the clinical IP development has been and will continue to represent the value driver for the share price.

In particular we are now awaiting the results of the in-human OSA trials and from my perspective the company’s decision to proceed towards a pre-IND meeting surely provides some insight into the status of this highly significant trial?

As a long-standing shareholder I’m very positive about the value drivers ahead, the current status of our trials and perhaps most importantly the calibre and leadership demonstrated by our board.